Shares of Piramal Pharma Ltd soared 4% on 23 January after the company’s division Piramal Critical Care announced the launching of Chlorpromazine Hydrochloride Injection, which will be offered in 25mg/1mL and 50mg/2 mL vials in the US. 

Chlorpromazine Hydrochloride Injection is a medication primarily used to manage various psychiatric disorders, including schizophrenia and psychotic conditions like paranoia (characterized by delusions and intense anxiety), mania (high energy and hyperactivity), anxiety, agitation, and impulsive behaviours that may pose risks.

PCC has added Chlorpromazine Hydrochloride to its growing lineup of generic injectables. This follows the 2024 launch of Edaravone IV Infusion. In 2023, PCC expanded its portfolio with the introductions of Pantoprazole Sodium for Injection, USP, and Doxycycline for Injection, USP, demonstrating its commitment to offering a comprehensive range of critical care products, the company said in a statement.

Peter DeYoung, Chief Executive Officer of Piramal Global Pharma, said, “We are thrilled to introduce Chlorpromazine Hydrochloride for Injection, USP, as part of our expanding US portfolio of injectable products at Piramal Critical Care. This launch complements our market-leading inhaled anesthesia products and reinforces our commitment to delivering critical care solutions to patients and healthcare providers worldwide.”

However, at 3:05 pm, the shares of Piramal Pharma shed all their early gains and were trading 1.30% lower at Rs 239.50 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!